{"classes":[{"categories":[{"measurements":[{"groupId":"OG011","spread":"17","value":"114"},{"groupId":"OG012","spread":"45.4","value":"141"},{"groupId":"OG013","spread":"25.7","value":"134"},{"groupId":"OG014","spread":"177","value":"437"},{"groupId":"OG015","spread":"159","value":"466"},{"groupId":"OG016","spread":"238","value":"601"},{"groupId":"OG017","spread":"163","value":"537"},{"groupId":"OG018","spread":"263","value":"637"},{"groupId":"OG019","spread":"207","value":"591"},{"groupId":"OG020","spread":"319","value":"789"},{"groupId":"OG021","spread":"441","value":"1290"},{"groupId":"OG022","spread":"353","value":"1190"},{"groupId":"OG023","spread":"412","value":"1080"},{"groupId":"OG024","spread":"335","value":"1110"},{"groupId":"OG025","spread":"264","value":"950"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"18"},{"groupId":"OG017","value":"5"},{"groupId":"OG018","value":"11"},{"groupId":"OG019","value":"7"},{"groupId":"OG020","value":"4"},{"groupId":"OG021","value":"10"},{"groupId":"OG022","value":"6"},{"groupId":"OG023","value":"11"},{"groupId":"OG024","value":"6"},{"groupId":"OG025","value":"6"}],"units":"Participants"}],"title":"Cycle 1, ROW patients"},{"categories":[{"measurements":[{"groupId":"OG011","spread":"131","value":"292"},{"groupId":"OG012","spread":"151","value":"268"},{"groupId":"OG013","spread":"196","value":"289"},{"groupId":"OG014","spread":"472","value":"816"},{"groupId":"OG015","spread":"673","value":"1340"},{"groupId":"OG016","spread":"447","value":"1180"},{"groupId":"OG017","spread":"563","value":"1020"},{"groupId":"OG018","spread":"572","value":"939"},{"groupId":"OG019","spread":"1450","value":"1500"},{"groupId":"OG020","spread":"150","value":"1860"},{"groupId":"OG021","spread":"645","value":"1950"},{"groupId":"OG022","spread":"531","value":"2840"},{"groupId":"OG023","spread":"828","value":"1440"},{"groupId":"OG024","spread":"874","value":"1510"},{"groupId":"OG025","spread":"700","value":"1310"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"5"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"12"},{"groupId":"OG017","value":"3"},{"groupId":"OG018","value":"7"},{"groupId":"OG019","value":"3"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"4"},{"groupId":"OG022","value":"2"},{"groupId":"OG023","value":"8"},{"groupId":"OG024","value":"5"},{"groupId":"OG025","value":"5"}],"units":"Participants"}],"title":"Cycle 3, ROW patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"20"},{"groupId":"OG017","value":"5"},{"groupId":"OG018","value":"11"},{"groupId":"OG019","value":"7"},{"groupId":"OG020","value":"4"},{"groupId":"OG021","value":"10"},{"groupId":"OG022","value":"6"},{"groupId":"OG023","value":"11"},{"groupId":"OG024","value":"6"},{"groupId":"OG025","value":"6"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUC calculation.\n\nJapanese patients were not treated with PDR001 and therefore the PK parameters of this study drug are not applicable.","dispersionType":"Standard Deviation","groups":[{"description":"Single-agent LAG525 1 mg/kg Q2W","id":"OG000","title":"Phase 1: LAG525 1 mg/kg Q2W"},{"description":"Single-agent LAG525 3 mg/kg Q2W","id":"OG001","title":"Phase 1: LAG525 3 mg/kg Q2W"},{"description":"Single-agent LAG525 5 mg/kg Q2W","id":"OG002","title":"Phase 1: LAG525 5 mg/kg Q2W"},{"description":"Single-agent LAG525 10 mg/kg Q2W","id":"OG003","title":"Phase 1: LAG525 10 mg/kg Q2W"},{"description":"Single-agent LAG525 15 mg/kg Q2W","id":"OG004","title":"Phase 1: LAG525 15 mg/kg Q2W"},{"description":"Single-agent LAG525 240 mg Q2W","id":"OG005","title":"Phase 1: LAG525 240 mg Q2W"},{"description":"Single-agent LAG525 400 mg Q2W","id":"OG006","title":"Phase 1: LAG525 400 mg Q2W"},{"description":"Single-agent LAG525 3 mg/kg Q4W","id":"OG007","title":"Phase 1: LAG525 3 mg/kg Q4W"},{"description":"Single-agent LAG525 5 mg/kg Q4W","id":"OG008","title":"Phase 1: LAG525 5 mg/kg Q4W"},{"description":"Single-agent LAG525 10 mg/kg Q4W","id":"OG009","title":"Phase 1: LAG525 10 mg/kg Q4W"},{"description":"Single-agent LAG525 400 mg Q4W","id":"OG010","title":"Phase 1: LAG525 400 mg Q4W"},{"description":"Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)","id":"OG011","title":"Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W"},{"description":"Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)","id":"OG012","title":"Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W"},{"description":"Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)","id":"OG013","title":"Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W"},{"description":"Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)","id":"OG014","title":"Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W"},{"description":"Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)","id":"OG015","title":"Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W"},{"description":"Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG016","title":"Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG017","title":"Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG018","title":"Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)","id":"OG019","title":"Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG020","title":"Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG021","title":"Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG022","title":"Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG023","title":"Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG024","title":"Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG025","title":"Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W"}],"paramType":"MEAN","populationDescription":"All patients in phase 1 who received at least one full or partial dose of PDR001 and who had at least one serum sample providing evaluable PK data.","reportingStatus":"POSTED","timeFrame":"pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).","title":"Phase 1: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PDR001","type":"SECONDARY","unitOfMeasure":"day*ug/mL"}